TG Therapeutics Inc (TGTX)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	25,583	-13,885	95,777	41,616	13,062	-25,906	-175,654	-168,554	-198,335	-238,679	-288,498	-326,485	-348,100	-342,979	-344,505	-318,892	-279,380	-230,734	-205,501	-188,830
Revenue (ttm)	US$ in thousands	329,004	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152
Pretax margin		7.78%	-5.29%	28.12%	14.85%	5.87%	-14.32%	-930.62%	-2,662.36%	-7,124.10%	-4,749.83%	-4,144.49%	-4,126.45%	-5,204.07%	-7,784.36%	-14,271.13%	-35,158.99%	-183,802.63%	-151,798.68%	-135,198.03%	-124,230.26%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $25,583K ÷ $329,004K
= 7.78%

TG Therapeutics Inc has shown a significant improvement in its pre-tax margin over the past few years. The company had negative pre-tax margins in the range of -124,230.26% to -183,802.63% in 2020, which improved gradually to -4,126.45% by the end of March 2022. Subsequently, the trend continued to improve, with the pre-tax margin reaching positive territory in December 2023 at 5.87%. This positive momentum was sustained into 2024, with the pre-tax margin increasing to 7.78% by December 31, 2024.

Overall, the company has successfully turned around its pre-tax margin from significant losses to profitability within a relatively short period. This improvement reflects positively on the company's financial performance and management's efforts in enhancing operational efficiency and controlling costs.